Figure 2.

Multivariable regression analyses of the association between possible predictors of leukocyte telomere length (LTL) at birth. A, Findings for all 185 participants (R² = 0.17). B, Findings for all 185 participants, with human immunodeficiency virus (HIV)–exposed, HIV-uninfected (HEU) children separated by type of combination antiretroviral therapy (cART) exposure in utero (R² = 0.20). C, Findings for 106 HEU children (R² = 0.19). D, Findings for 79 HIV-unexposed, HIV-uninfected (HUU) children (R² = 0.18). Effect sizes are expressed as nonstandardized β values. Strong collinearity between gestational age and birth weight was detected and precluded inclusion of both variables in the same model. Separate models that included either gestational age or birth weight were constructed, but the latter explained a greater portion of the variance (ie, it had a higher R²) and was chosen as the best model. ABC, abacavir; AZT, zidovudine; CI, confidence interval; FTC, emtricitabine; LPV/r, ritonavir-boosted lopinavir; NFV, nelfinavir; NVP, nevirapine; PI/r, ritonavir-boosted protease inhibitor; TDF, tenofovir disoproxil fumarate; 3TC, lamivudine. ^aEight HEU children who were exposed to nonstandard cART regimen in utero were excluded from these analyses.